Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
META-3
- Development stage
- Preclinical
- Lead developer
- META Pharmaceuticals
- Modality
- Small Molecules
01
Overview
META-3 is an investigational small molecule immunometabolism modulator being developed by META Pharmaceuticals for the treatment of pneumonia and other pulmonary diseases. The drug is designed to target pyruvate dehydrogenase kinase 1 (PDK1), a key enzyme that regulates the metabolic switch in immune cells such as macrophages and neutrophils. By inhibiting PDK1, META-3 aims to reprogram these cells from a pro-inflammatory glycolytic state to a more balanced metabolic profile, thereby reducing the excessive inflammation and tissue damage associated with acute lung injury and severe respiratory infections. Currently in the preclinical stage, META-3 represents a novel therapeutic approach that targets the metabolic drivers of immune-mediated pulmonary damage to restore respiratory homeostasis.
02
Targets
PDK (Pyruvate dehydrogenase kinase isoform 1)
Beyond the preview
Go deeper on META-3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on META-3.